Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Paciocco

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
The European Respiratory Journal|March 18, 2022
The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?Roberto Badagliacca, Silvia Papa, Michele D'Alto, et al.
ESC Heart Failure|February 19, 2026
Value of right heart haemodynamics for risk stratification of patients with pulmonary arterial hypertension at follow-upLaura Scelsi, Roberto Badagliacca, Michele D'Alto, et al.
Circulation. Heart Failure|September 17, 2025
TAPSE/sPAP Ratio to Improve Risk Assessment in Pulmonary Arterial HypertensionRoberto Badagliacca, Khodr Tello, Michele D'Alto, et al.
Vascular Pharmacology|March 1, 2026
2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspectiveGiovanna Manzi, Roberto Badagliacca, Michele D'Alto, et al.
Vascular Pharmacology|December 1, 2025
ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of REVEAL risk scoreSilvia Papa, Michele D'Alto, Laura Scelsi, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
The European Respiratory Journal|March 18, 2022
The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?Roberto Badagliacca, Silvia Papa, Michele D'Alto, et al.
ESC Heart Failure|February 19, 2026
Value of right heart haemodynamics for risk stratification of patients with pulmonary arterial hypertension at follow-upLaura Scelsi, Roberto Badagliacca, Michele D'Alto, et al.
Circulation. Heart Failure|September 17, 2025
TAPSE/sPAP Ratio to Improve Risk Assessment in Pulmonary Arterial HypertensionRoberto Badagliacca, Khodr Tello, Michele D'Alto, et al.
Vascular Pharmacology|March 1, 2026
2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspectiveGiovanna Manzi, Roberto Badagliacca, Michele D'Alto, et al.
Vascular Pharmacology|December 1, 2025
ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of REVEAL risk scoreSilvia Papa, Michele D'Alto, Laura Scelsi, et al.
Pageof 3